NeuroPace Inc. Files 8-K Report
Ticker: NPCE · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1528287
| Field | Detail |
|---|---|
| Company | Neuropace Inc (NPCE) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
NeuroPace filed an 8-K on Jan 28, 2025, updating on operations and financials.
AI Summary
On January 28, 2025, NeuroPace Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 455 N. Bernardo Avenue, Mountain View, CA 94043. The report covers items related to the company's results of operations, financial condition, Regulation FD disclosures, and other events.
Why It Matters
This 8-K filing provides an update on NeuroPace Inc.'s operational and financial status, which is crucial for investors to understand the company's current standing.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate information and updates, not indicating any immediate significant risks.
Key Players & Entities
- NeuroPace Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- 455 N. Bernardo Avenue, Mountain View, CA 94043 (location) — Principal executive offices
- Delaware (jurisdiction) — State of Incorporation
- 001-40337 (identifier) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for NeuroPace Inc.?
The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering items related to Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 28, 2025.
Where are NeuroPace Inc.'s principal executive offices located?
NeuroPace Inc.'s principal executive offices are located at 455 N. Bernardo Avenue, Mountain View, CA 94043.
In which U.S. state was NeuroPace Inc. incorporated?
NeuroPace Inc. was incorporated in Delaware.
What is the SEC file number for NeuroPace Inc.?
The SEC file number for NeuroPace Inc. is 001-40337.
Filing Stats: 1,478 words · 6 min read · ~5 pages · Grade level 14.3 · Accepted 2025-01-28 17:25:58
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NPCE The Nasdaq
Filing Documents
- d877194d8k.htm (8-K) — 40KB
- d877194dex991.htm (EX-99.1) — 13KB
- g877194g0129023300775.jpg (GRAPHIC) — 4KB
- 0001193125-25-014473.txt ( ) — 185KB
- npce-20250128.xsd (EX-101.SCH) — 3KB
- npce-20250128_lab.xml (EX-101.LAB) — 18KB
- npce-20250128_pre.xml (EX-101.PRE) — 11KB
- d877194d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and Private Securities Litigation Reform Act made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "forecasts," "intends," "may," "plans," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: preliminary financial results for the fourth fiscal quarter and full year 2024; the Company's current expectations with respect to its clinical development programs, including progress and timing of the NAUTILUS pivotal trial and related regulatory submission, and the Company's collaboration with NEST and the FDA for the potential use of PERC's data in a regulatory submission for pediatric focal epilepsy; and the Company's planned release of a new PDMS feature. Actual results or events could differ materially from the plans and expectations disclosed in these forward-looking statements as a result of various factors, including: actual operating results may differ significantly from any guidance provided; uncertainties related to market acceptance and adoption of the RNS System; uncertainties inherent in the progress and completion of clinical trials and clinical development of the RNS System; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for the Company's RNS System; uncertainties related to product development and associated timelines; and other important factors. These and other risks and uncertainties include those described more fully
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release dated January 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NeuroPace, Inc. Dated: January 28, 2025 By: /s/ Rebecca Kuhn Rebecca Kuhn Chief Financial Officer and Vice President, Finance and Administration